Kuehn Law Encourages DSKE, RYZB, ROVR, and GRPH Investors to Contact Law Firm
02. Februar 2024 11:58 ET
|
KUEHN LAW, PLLC
Kuehn Law investigates DSKE, RYZB, ROVR, GRPH mergers for shareholder rights, seeking fair process and disclosures.
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – AMAM, CSTR, RYZB, THRX
24. Januar 2024 17:16 ET
|
Monteverde & Associates PC
NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – RYZB, THRX, AMAM, CSTR
19. Januar 2024 20:00 ET
|
Monteverde & Associates PC
NEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
STOCKHOLDER ALERT: Juan Monteverde Encourages the Shareholders of HARP, VIA, RYZB, FGH to Take Action
09. Januar 2024 17:36 ET
|
Monteverde & Associates PC
NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
SHAREHOLDER ALERT: Juan Monteverde Encourages the Shareholders of GRCL, RYZB, CVLY, WAVD to Take Action
04. Januar 2024 20:00 ET
|
Monteverde & Associates PC
NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
ALERT: Juan Monteverde Encourages the Shareholders of RYZB, GRCL, X, PGTI to Take Action
26. Dezember 2023 18:01 ET
|
Monteverde & Associates PC
NEW YORK, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
RYZB News: Johnson Fistel Investigates Proposed Sale of RayzeBio; Is $62.50 a Fair Price?
26. Dezember 2023 09:23 ET
|
Johnson Fistel, LLP
On December 26, 2023, RayzeBio announced that it had entered a deal with Bristol Myers Squibb.
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
26. Dezember 2023 07:13 ET
|
Rayzebio, Inc.
Transaction Brings RayzeBio’s Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb’s Leading Oncology...
RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors
01. November 2023 06:00 ET
|
Rayzebio, Inc.
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today...